These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 28556284)

  • 1. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
    Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
    Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
    Goldfischer E; Kowalczyk JJ; Clark WR; Brady E; Shane MA; Dgetluck N; Klise SR
    Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA].
    Hayashi K; Fukagai T; Koshikiya A; Igarashi A; Morita M; Sasaki H; Ishikawa K
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):28-33. PubMed ID: 28132988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
    Takeda M; Yokoyama O; Lee SW; Murakami M; Morisaki Y; Viktrup L
    Int J Urol; 2014 Jul; 21(7):670-5. PubMed ID: 24571205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
    Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
    BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study.
    Zhang Z; Li H; Zhang X; Dai Y; Park HJ; Jiann BP; Li P; Lou Y; Ye Z; Viktrup L
    Int J Urol; 2019 Feb; 26(2):192-200. PubMed ID: 30362173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.